To help employers, health plans, and pharmacy benefit managers deliver best-in-class outcomes with or without GLP-1 medications, Virta recently launched Responsible Prescribing, an expansion of its SWL suite.

Physicians Reveals GLP-1s for Weight Loss are Overprescribed and Unsustainable by Jasmine Pennic 08/06/2024 Leave a Comment What You Should Know:  – A large majority of physicians feel GLP-1s are being overprescribed, according to a new survey from Virta Health, a leader in type 2 diabetes reversal.  – The Virta Health survey was conducted in partnership with Beresford Research and included 300 primary care providers, endocrinologists, and obesity specialists across the United States sheds light on the medical community’s views on the rapidly growing class of GLP-1 medications, often hailed as “miracle drugs” for weight loss.  Key Findings Reveals Skepticism About Weight Loss Drugs The key findings reveal significant concerns about the long-term efficacy, potential side effects, and overall impact of these medications on public health:  – Doubtful about long-term efficacy: Most physicians believe GLP-1 medications are not sustainable beyond two to three years and should not be used as a long-term solution. – Overprescription concerns: A large majority of physicians feel GLP-1s are being overprescribed and that lifestyle interventions should be prioritized. – Need for stricter guidelines: Physicians advocate for increased oversight through prior authorization and greater provider involvement in prescribing decisions. – Patient misconceptions: Many doctors report that patients have unrealistic expectations about the effectiveness and safety of GLP-1 medications. – Potential for increased healthcare costs: The widespread adoption of GLP-1s is expected to drive up healthcare costs due to increased demand and limited supply. – Concerns about health equity: Physicians are worried about the potential for increased health disparities as GLP-1 medications may not be equally accessible to all patients